{"nctId":"NCT05046795","briefTitle":"Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)","startDateStruct":{"date":"2021-11-10","type":"ACTUAL"},"conditions":["COPD"],"count":258,"armGroups":[{"label":"Revefenacin inhalation solution 175 mcg QD.","type":"EXPERIMENTAL","interventionNames":["Drug: Revefenacin 175 mcg in 3 ML Inhalation Solution"]},{"label":"Placebo inhalation solution QD.","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo inhalation solution QD"]}],"interventions":[{"name":"Revefenacin 175 mcg in 3 ML Inhalation Solution","otherNames":[]},{"name":"Placebo inhalation solution QD","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Key inclusion criteria include:\n\n  * Males and females of Chinese ethnicity, at least 40 years of age. Females may be of either childbearing or non-childbearing potential. All females of childbearing potential must be using an acceptable, highly effective method of contraception and have a negative pregnancy test at screening.\n  * A clinical diagnosis for at least 6 months prior to screening of COPD according to Global Initiative for Chronic Obstructive Lung Disease(GOLD) guidelines.\n  * Subject is capable of performing reproducible spirometry maneuvers as described by current American Thoracic Society/European Respiratory Society (ATS/ERS) Guidelines and has a post-ipratropium (500 mcg nebulized) Forced Expiratory Volume in\n\n    1 second(FEV1)/Forced Vital Capacity(FVC) ratio \\<0.7 at Visit 2.\n  * Subject has moderate to very severe COPD with a post-ipratropium (500 mcg nebulized) FEV1 less than 80% of predicted normal (using the Global Lung Function Initiative reference range; ) and an absolute FEV1 \\>700 mL at Visit 2\n  * Current smoker or ex-smoker, with a history of at least 10 pack-years of tobacco smoking. Ex-smokers must have stopped smoking \\>6 months prior to Visit 1.\n\nExclusion Criteria:\n\n* Key exclusion criteria include:\n\n  * Previously dosed with Revefenacin.\n  * Current diagnosis of asthma.\n  * Alpha-1 anti-trypsin deficiency.\n  * Other chronic or active respiratory disorder (e.g., clinically significant \\[as determined by the Investigator\\] bronchiectasis, pulmonary fibrosis, sarcoidosis, pneumoconiosis, active tuberculosis).\n  * Symptoms of, or treatment for an Acute Exacerbation of COPD(AECOPD) requiring antibiotics and/or oral/systemic corticosteroids or in-patient hospitalization during the 28 days preceding screening or during the screening period between Visit 1 and Visit 3.\n  * Pneumonia requiring hospitalization within 28 days prior to screening or during the screening period between Visit 1 and Visit 3.\n  * Lower respiratory tract infection requiring treatment with antibiotics during the 28 days preceding screening or during the screening period between Visit 1 and Visit 3.\n  * History or presence of pulmonary hypertension, respiratory failure, cor pulmonale or right ventricular failure which may impact the safety of the subject in the clinical judgement of the Investigator.\n  * History of pulmonary lobectomy, lung volume reduction surgery, or lung transplantation.\n  * Use of supplemental oxygen therapy for more than 15 hours per day (includes night-time use).\n  * Subjects with hepatic impairment.\n  * Subject suffers from any medical condition that would preclude the use of inhaled anticholinergics, including narrow-angle glaucoma, symptomatic benign prostatic hyperplasia, bladder neck obstruction, or urinary retention.\n  * Subjects who are unable to stop any of the following medications, and refrain from their use throughout the study until the final dose of study drug:\n\n    * Short-acting β2 agonists (except study-supplied salbutamol).\n    * Short-acting anticholinergic agents (except those used for reversibility testing).\n    * Long-acting anticholinergics (except study supplied medication).\n    * Combination β2 agonists/anticholinergic agents.\n    * Combination β2 agonists/inhaled corticosteroids/anticholinergic agents.\n    * Phosphodiesterase 4 inhibitors.\n    * Theophyllines.\n    * Leukotriene inhibitors.\n    * Orally inhaled nedocromil or cromolyn sodium.\n    * Oral or parenteral corticosteroids.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Trough FEV1 on Day 85","description":"Change from Baseline (Day 1, pre-dose) trough FEV1 on Day 85","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.12","spread":"23.974"},{"groupId":"OG001","value":"-95.78","spread":"24.504"}]}]}]},{"type":"PRIMARY","title":"Trough FEV1 on Day 85 - Sensitivity Analysis With Missing Data Imputed","description":"Sensitivity analysis results of change from baseline in trough FEV1 (mL) on Day 85 with missing data imputed by last observation carried forward","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.05","spread":"27.036"},{"groupId":"OG001","value":"-92.30","spread":"27.502"}]}]}]},{"type":"SECONDARY","title":"Trough FVC on Day 85","description":"Change from baseline (Day 1, pre-dose) trough Forced Vital Capacity (FVC) on Day 85","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.92","spread":"41.833"},{"groupId":"OG001","value":"-189.83","spread":"42.801"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Peak FEV1 (0-2h) on Day 1","description":"Baseline FEV1 was defined as the average of the -45 and -15 minute measurements prior to dosing of study drug on Day 1. Peak FEV1 (0-2h) was defined as the highest post dose FEV1 value within 2 hours after the dosing.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"234.2","spread":"21.55"},{"groupId":"OG001","value":"128.4","spread":"21.92"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Peak FEV1 (0-2h) on Day 85","description":"Baseline FEV1 was defined as the average of the -45 and -15 minute measurements prior to dosing of study drug on Day 1. Peak FEV1 (0-2h) was defined as the highest post dose FEV1 value within 2 hours after the dosing.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"199.0","spread":"32.72"},{"groupId":"OG001","value":"44.2","spread":"33.62"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SGRQ Total Score on Day 85","description":"Change from Baseline in the St George's Respiratory Questionnaire (SGRQ) Total Score on Day 85.\n\nScores range from 0 to 100, with higher scores indicating more health limitations. A reduction of 4 or more points is considered to be a clinically meaningful improvement","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"2.17"},{"groupId":"OG001","value":"0.2","spread":"2.20"}]}]}]},{"type":"SECONDARY","title":"Number (%) of SGRQ Responders on Day 85","description":"Number of subjects with a decrease from baseline of ≥4 units in SGRQ total score (which was defined as a responder) on Day 85","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":129},"commonTop":["COPD","COVID-19","Upper respiratory tract infection","Chest discomfort","Dyspnea"]}}}